| Identification | Back Directory | [Name]
Inebilizumab | [CAS]
1299440-37-1 | [Synonyms]
Inebilizumab
Inebilizumab (anti-CD19)
Research Grade Inebilizumab(DHD10802) |
| Hazard Information | Back Directory | [Uses]
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1]. | [in vivo]
Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2]. | Animal Model: | huCD19/CD20 double Tg mice[2] | | Dosage: | 0.5, 2, or 10 mg/kg | | Administration: | Tail vein injection, once | | Result: | Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages. |
| [References]
[1] Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5(12):107. DOI:10.3390/jcm5120107
[2] Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. DOI:10.1124/jpet.110.168062 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
|